Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) represent distinct gastrointestinal disorders that both cause chronic abdominal symptoms, though their pathophysiology, treatment approaches, and prognosis differ fundamentally. IBS is a disorder of gut-brain interaction with altered motility and visceral hypersensitivity, while IBD involves immune-mediated chronic inflammation of the gastrointestinal tract.
What Are IBS and IBD Pharmacotherapy?
IBS pharmacotherapy targets symptom relief through modulation of motility, secretion, visceral sensation, and the gut microbiome. IBD treatment aims to control inflammation, induce and maintain remission, prevent complications, and improve quality of life through immunosuppressive and biologic therapies.
Drug Classes and Mechanisms
Antispasmodics including hyoscine butylbromide, mebeverine, and peppermint oil reduce smooth muscle spasm in IBS through anticholinergic or calcium channel blocking effects, providing relief of abdominal cramping and bloating.
Fiber supplementation with psyllium or other soluble fibers improves stool consistency in both constipation-predominant and diarrhea-predominant IBS, though insoluble fibers may worsen symptoms.
Tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline at low doses reduce visceral hypersensitivity and prolong colonic transit time. They are effective for global IBS symptoms, particularly in diarrhea-predominant disease.
5-HT4 agonists like tegaserod stimulate peristalsis and accelerate gastrointestinal transit in constipation-predominant IBS. 5-HT3 antagonists such as alosetron reduce colonic transit and visceral pain in severe diarrhea-predominant IBS but carry a risk of ischemic colitis.
Rifaximin is a minimally absorbed antibiotic that alters gut microbiota, reducing bloating and stool frequency in diarrhea-predominant IBS. Lubiprostone and linaclotide, described previously, are effective in constipation-predominant IBS.
5-aminosalicylates (5-ASA) including mesalamine, sulfasalazine, and balsalazide are first-line therapy for mild-to-moderate ulcerative colitis. They inhibit inflammatory pathways in the colonic mucosa through multiple mechanisms including peroxisome proliferator-activated receptor gamma activation.
Corticosteroids such as prednisone and budesonide provide rapid anti-inflammatory effects in moderate-to-severe IBD flares but are not suitable for maintenance therapy due to systemic adverse effects.
Immunomodulators including azathioprine, 6-mercaptopurine, and methotrexate inhibit lymphocyte proliferation and are used for steroid-sparing maintenance therapy in moderate-to-severe IBD.
Biologics include anti-TNF agents (infliximab, adalimumab, golimumab), anti-integrins (vedolizumab), and anti-IL-12/23 agents (ustekinumab). These targeted therapies neutralize specific inflammatory cytokines or block lymphocyte trafficking to the gut.
Therapeutic Uses
IBS treatment follows a symptom-based algorithm: antispasmodics for pain, laxatives for constipation, loperamide for diarrhea, low-dose TCAs for moderate-to-severe symptoms. IBD treatment is stepped up based on disease severity: 5-ASA for mild ulcerative colitis, corticosteroids for flares, immunomodulators for maintenance, and biologics for refractory or severe disease.
Adverse Effects
TCAs cause sedation, dry mouth, and constipation. Alosetron carries ischemic colitis risk requiring strict prescribing restrictions. 5-ASA agents may cause nephrotoxicity requiring renal monitoring. Corticosteroids cause weight gain, osteoporosis, diabetes, and adrenal suppression. Immunomodulators require monitoring for myelosuppression, hepatotoxicity, and lymphoma risk. Biologics increase infection risk and require tuberculosis screening before initiation.
Key Clinical Considerations
IBS is a diagnosis of exclusion, and treatment must be individualized based on predominant symptom pattern and severity. IBD requires close monitoring of disease activity with objective markers including endoscopy and fecal calprotectin. Therapeutic drug monitoring of biologics improves outcomes. Smoking worsens Crohn’s disease but may improve ulcerative colitis.
Conclusion
IBS and IBD require distinct therapeutic strategies reflecting their different pathophysiologies. Recent advances in IBS therapeutics and the expanding biologic armamentarium for IBD have significantly improved symptom control and disease outcomes for patients with these chronic conditions.
